These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6338979)

  • 1. A technique for specific removal of factor IX alloantibodies from human plasma: partial characterization of the alloantibodies.
    Theodorsson B; Hedner U; Nilsson IM; Kisiel W
    Blood; 1983 May; 61(5):973-81. PubMed ID: 6338979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An agarose plate method for detecting alloantisera to coagulant factor IX and factor IX antigen.
    Reisner HM; Strand EA; Chung KS; Roberts HR
    Br J Haematol; 1980 Feb; 44(2):313-21. PubMed ID: 7378302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloantibodies to factor IX in Haemophilia B characterized by crossed immunoelectrophoresis and enzyme-conjugated antisera to human immunoglobulins.
    Orstavik KH
    Br J Haematol; 1981 May; 48(1):15-23. PubMed ID: 6788066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction.
    Lewis RM; Reisner HM; Chung KS; Roberts HR
    Blood; 1980 Oct; 56(4):608-14. PubMed ID: 6158351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apheresis.
    Nilsson IM; Freiburghaus C
    Adv Exp Med Biol; 1995; 386():175-84. PubMed ID: 8851026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.
    Giddings JC; Bloom AL; Kelly MA; Spratt HC
    Clin Lab Haematol; 1983; 5(2):165-75. PubMed ID: 6603957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of IgG heavy chain subclasses of alloantibodies to factor IX by crossed immunoelectrophoresis of factor IX using the intermediate gel technique.
    Iizuka A; Nagao T
    Br J Haematol; 1983 Apr; 53(4):687-8. PubMed ID: 6403026
    [No Abstract]   [Full Text] [Related]  

  • 10. Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
    Thompson AR
    J Clin Invest; 1977 May; 59(5):900-10. PubMed ID: 856873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
    Michalski C; Bal F; Burnouf T; Goudemand M
    Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
    Boylan B; Rice AS; Neff AT; Manco-Johnson MJ; Kempton CL; Miller CH;
    J Thromb Haemost; 2016 Oct; 14(10):1931-1940. PubMed ID: 27501440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
    Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
    Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation and characterization of canine factor IX.
    Sugahara Y; Catalfamo J; Brooks M; Hitomi E; Bajaj SP; Kurachi K
    Thromb Haemost; 1996 Mar; 75(3):450-5. PubMed ID: 8701406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
    Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
    Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of CNBr, FMP and hydrazide resins for immunoaffinity purification of factor IX.
    Highsmith F; Regan T; Clark D; Drohan W; Tharakan J
    Biotechniques; 1992 Mar; 12(3):418-23. PubMed ID: 1571154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
    Griffith MJ; Breitkreutz L; Trapp H; Briet E; Noyes CM; Lundblad RL; Roberts HR
    J Clin Invest; 1985 Jan; 75(1):4-10. PubMed ID: 3871202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.
    Liebman HA; Limentani SA; Furie BC; Furie B
    Proc Natl Acad Sci U S A; 1985 Jun; 82(11):3879-83. PubMed ID: 2408269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid purification of factor IX, factor X and prothrombin by immunoaffinity and ion exchange chromatography.
    Ahmad SS; Rawala-Sheikh R; Thompson AR; Walsh PN
    Thromb Res; 1989 Jul; 55(1):121-33. PubMed ID: 2781515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A method for systematic purification from bovine plasma of six vitamin K-dependent coagulation factors: prothrombin, factor X, factor IX, protein S, protein C, and protein Z.
    Hashimoto N; Morita T; Iwanaga S
    J Biochem; 1985 May; 97(5):1347-55. PubMed ID: 3161875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.